Journal Basic Info
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.Major Scope
- Pancreatic Cancer
- Urological Cancers
- Colon Cancer
- Brain and Spinal Cord Cancer
- Gastrointestinal Cancer
- Targeted Therapy
- Surgical Oncology
- Central Nervous System Tumors
Abstract
Citation: Clin Oncol. 2017;2(1):1183.DOI: 10.25107/2474-1663.1183
LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
Arvind Jain, Jing Zhang and Terence Rabbitts
Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK
*Correspondance to: Terence Rabbitts
PDF Full Text Review Article | Open Access
Abstract:
Ewing sarcoma is a predominantly paediatric cancer with a high rate of metastasis and reoccurrence. A new surface marker called LINGO-1 was recently identified on Ewing tumours as a potential target for antibody-mediated therapies. However, such targeting requires caution because of LINGO-1 expression on some brain cells. Although the blood-brain-barrier exists, small amounts of antibody may cross this barrier and cause harmful side-effects. In this perspective, we suggest some options to alleviate this risk that can make targeting tumour cells expressing the LINGO-1 antigen a safe option.
Keywords:
Ewing sarcoma; Chromosomal translocation; Antibody; Single domains; iDAb; LINGO-1; ADC; Nanoparticles
Cite the Article:
Jain A, Zhang J, Rabbitts T. LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma. Clin Oncol. 2017;2: 1183.
